Insights from 2023 ASH Annual Meeting

 

Insights from 2023 ASH Annual Meeting
D

Prevalence and Prediction of Ruxolitinib Treatment Emergent Thrombocytopenia in Myelofibrosis

By Insights from 2023 ASH Annual Meeting FEATURING Douglas Tremblay
By Insights from 2023 ASH Annual Meeting FEATURING Douglas Tremblay
402 views
December 13, 2023
0 Comments
Login to view comments. Click here to Login

Featured Video

16:51
Incyte

Effects of PV Treatment on White Blood Cell Count and Thrombotic Risk

Feat. C. Harrison

Featured Video

16:26
Incyte

Effects of a Treatment Option on Hematocrit Control and Spleen Volum…

Feat. C. Harrison
MDS and MPN
21:52
Insights from 2023 ASH Annual Meeting

ASH 2023 Summary: "MF, ET, and PV - Highlights and Clinical Imp…

Feat. D. Tremblay
10:02
Insights from 2023 ASH Annual Meeting

ASH 2023 Summary: "The Best of MPNs - Highlights & Key Take…

Feat. R. Mesa
12:38
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "LIMBER-103 Study - BETi INCB057643 in Pts W…

Feat. J. Watts
08:18
Insights from 2023 ASH Annual Meeting

Treatment Strategies for Hematocrit Control in PV

Feat. A. Zhou
05:44
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Study of Add-on Therapy With CK0804 in Pati…

Feat. L. Masarova
12:21
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "PIM1 Kinase Inhibitor TP-3654 for R/R Myelo…

Feat. L. Rein
11:20
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Validation of the Composite CR Definitions …

Feat. J. Bewersdorf
13:24
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "MATTERHORN Study - Efficacy & Safety of…

Feat. M. Mittelman
06:46
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Guadecitabine in Higher-Risk MDS and CMML U…

Feat. S. Urrutia
06:38
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "FREEDOM2 Study of Fedratinib in Patients Wi…

Feat. C. Harrison
10:40
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Durable Clinical Benefit With KER-050 (Elri…

Feat. M. Diez-Campelo
06:51
Insights from 2023 ASH Annual Meeting

Prevalence and Prediction of Ruxolitinib Treatment Emergent Thromboc…

Feat. D. Tremblay